当前位置: 首页 >> 检索结果
481. Circulating PD-1hi CXCR5- and CXCR5+ CD4 T cells are elevated in patients with newly diagnosed Giant Cell Arteritis and predict relapse.
作者: Irene Monjo.;Beatriz Nieto-Carvalhal.;Mariela Uyaguari.;Sara García-Carazo.;Alejandro Balsa.;Eugenio de Miguel.;María-Eugenia Miranda-Carús.
来源: Rheumatology (Oxford). 2025年
Giant cell arteritis (GCA) is a large/medium-vessel granulomatous vasculitis, and the PD-1/PD-L1 coinhibitory pathway seems to be implicated in its pathogenesis. CD4 T cells expressing high PD-1 levels, CD4+CXCR5-PD-1hi peripheral helper (Tph) and CD4+CXCR5+PD-1hi follicular helper T cells (Tfh), are key mediators of autoimmunity. Their frequencies are elevated in the peripheral blood of subjects with several autoimmune conditions but have not been investigated in GCA. Our objective was to study the frequency of circulating Tph (cTph) and Tfh (cTfh) in patients with newly diagnosed GCA (nGCA).
482. Optical spectral transmission to monitor disease activity in arthritis patients: longitudinal follow-up comparison with clinical parameters.
作者: Konstantinos Triantafyllias.;Mohammed Alhaddad.;Xenofon Baraliakos.;Muthuraman Muthuraman.;Andreas Schwarting.
来源: Rheumatology (Oxford). 2025年
To examine the longitudinal associations of optical spectral transmission (OST) with clinical inflammatory arthritis activity markers in order to investigate its potential in monitoring disease activity.
483. Tocilizumab and rituximab for systemic sclerosis interstitial lung disease: a real-world cohort analysis.
作者: Nina R Goldman.;Svetlana I Nihtyanova.;Claire F Beesley.;Athol U Wells.;Christopher P Denton.;Elisabetta A Renzoni.;Rizgar Mageed.;Voon H Ong.
来源: Rheumatology (Oxford). 2025年
Systemic sclerosis (SSc)-interstitial lung disease (ILD) is one of the leading causes of mortality in SSc. Data from randomised controlled trials (RCTs) supports rituximab and tocilizumab monotherapy but there is limited data regarding their use for those who fail standard immunomodulatory therapies.
485. Association between red blood cell distribution width and genetic risk in patients with rheumatoid arthritis: a prospective cohort study and Mendelian randomization analysis.
作者: Mingyang Chen.;Jing Lei.;Zhenqiu Liu.;Renjia Zhao.;Yanfeng Jiang.;Kelin Xu.;Tiejun Zhang.;Chen Suo.;Xingdong Chen.
来源: BMC Rheumatol. 2025年9卷1期1页
Elevated red blood cell distribution width (RDW) is associated with increased risk of rheumatoid arthritis (RA), but the potential interactions of RDW with genetic risk of incident RA remain unclear. This study aimed to investigate the associations between RDW, genetics, and the risk of developing RA.
487. Comparative effectiveness of disease modifying antirheumatic drugs for patients with cardiac sarcoidosis.
作者: Lisbeth Brooks.;William Kivlin.;Divyanshu Mohananey.;Viktoriya Sabchyshyn.;Michael Putman.
来源: Rheumatology (Oxford). 2024年
We aimed to evaluate the comparative efficacy of disease modifying antirheumatic drugs (DMARDs) for patients with cardiac sarcoidosis.
490. Dermatology response to the Hyperinflammation and HLH Across Specialty Collaboration consensus guideline - Authors' reply.
作者: Aisling S Carr.;Ben Carpenter.;Ian Proctor.;Bethany Brockbank.;Evangelia Panagou.;Rachel Tattersall.;Satyen Gohil.;Jessica J Manson.
来源: Lancet Rheumatol. 2025年7卷1期e10-e11页 492. Evaluation of hematological markers as prognostic tools in rheumatoid arthritis.
作者: Maryam Masoumi.;Maryam Bozorgi.;Zahra Nourmohammadi.;Mohammad Javad Mousavi.;Aref Shariati.;Jafar Karami.
来源: BMC Rheumatol. 2024年8卷1期75页
Reducing inflammation is central to the management of RA. However, commonly used markers such as CRP and ESR, along with the DAS-28 score, have shown limitations. Hematologic indices, such as platelet-lymphocyte ratio (PLR), lymphocyte-monocyte ratio (LMR), and neutrophil-lymphocyte ratio (NLR), show potential as reliable indicators of inflammation in RA. This study evaluates these markers across different RA activity levels to identify effective biomarkers for distinguishing active RA from remission.
493. Association of patient- and hospital-level predictors with patterns of initial treatment in patients with Rheumatoid Arthritis: findings from a national cohort study.
作者: Zijing Yang.;Edward Alveyn.;Mark Russell.;Katie Bechman.;Callum Coalwood.;Elizabeth Price.;Abhishek Abhishek.;Sam Norton.;James Galloway.
来源: Rheumatology (Oxford). 2024年
To update the first-line conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) prescribing pattern, describe change and variation across demographical and geographical factors in the Rheumatoid arthritis (RA) population, and identify individual and hospital factors associated with it.
494. Predictors of rituximab efficacy in systemic sclerosis-associated interstitial lung disease: machine-learning analysis of the DESIRES trial.
作者: Ai Kuzumi.;Koji Oba.;Satoshi Ebata.;Kosuke Kashiwabara.;Keiko Ueda.;Yukari Uemura.;Takeyuki Watadani.;Takemichi Fukasawa.;Shunsuke Miura.;Asako Yoshizaki-Ogawa.;Hidenori Kage.;Shinichi Sato.;Ayumi Yoshizaki.
来源: Rheumatology (Oxford). 2024年
Rituximab is emerging as a promising therapeutic option for systemic sclerosis-associated interstitial lung disease (SSc-ILD). However, little is known about factors that predict the efficacy of rituximab in SSc-ILD.
495. Remission of lymphoma and rheumatoid arthritis following anti-CD19 chimeric antigen receptor T-cell therapy for diffuse large B-cell lymphoma.
作者: Aliya Masihuddin.;Jason Liebowitz.;Ran Reshef.;Joan Bathon.
来源: Rheumatology (Oxford). 2025年64卷5期3183-3185页 496. The impact of an online, lifestyle intervention program on the lives of patients with a rheumatic and musculoskeletal disease: a pilot study.
作者: K Van Slingerland.;L J C Kranenburg.;N Wilmsen.;E Coles.;R J E M Dolhain.;P H P de Jong.
来源: Rheumatology (Oxford). 2024年
To evaluate the short and long term effects of an online, interactive, multifactorial lifestyle intervention program (Leef! Met Reuma) on health risk and all ICHOM-recommended patient reported outcome measures(PROMs) in patients with an Inflammatory Arthritis(IA), OsteoArthritis(OA) or FibroMyalgia(FM).
499. Allogeneic haematopoietic stem-cell transplantation for children with refractory systemic juvenile idiopathic arthritis and associated lung disease: outcomes from an international, retrospective cohort study.
作者: Michael G Matt.;Daniel Drozdov.;Elisabeth Bendstrup.;Mia Glerup.;Ellen-Margrethe Hauge.;Tania Masmas.;Elvira Cannizzaro Schneider.;Ulrike B Zeilhofer.;Rolla F Abu-Arja.;Kyla D Driest.;Joseph H Oved.;Karen Onel.;Christen L Ebens.;Deepakbabu Chellapandian.;Shanmuganathan Chandrakasan.;Sampath Prahalad.;Johannes Roth.;Susan E Prockop.;Juliana Silva.;Andrew H Schapiro.;Christopher Towe.;Sharat Chandra.;Alexei Grom.;Grant S Schulert.;Rebecca A Marsh.
来源: Lancet Rheumatol. 2025年7卷4期e243-e251页
Systemic juvenile idiopathic arthritis-related lung disease (sJIA-LD) is a severe complication in patients with treatment-refractory systemic juvenile idiopathic arthritis (sJIA). The objective of this study was to evaluate the effect of allogeneic haematopoietic stem-cell transplantation (HSCT) in a cohort of children with sJIA-LD.
500. Sustained DMARD-free remission in subgroups of patients with rheumatoid arthritis: an analysis of two prospective cohorts with early arthritis.
作者: Judith W Heutz.;Pascal H P de Jong.;Marloes Verstappen.;Annette H M van der Helm-van Mil.;Elise van Mulligen.
来源: Lancet Rheumatol. 2025年7卷4期e252-e260页
About 20% of patients with rheumatoid arthritis on disease-modifying antirheumatic drugs (DMARDs) can reach sustained DMARD-free remission. Nonetheless, the 2022 EULAR recommendations discourage complete cessation of DMARDs due to flare risk. The evidence behind this recommendation is obtained from trial populations using biological DMARDs, representing only a subgroup of the total population of patients with rheumatoid arthritis. We hypothesised that patients requiring biological DMARDs represent a subgroup that is less capable of reaching sustained DMARD-free remission compared with patients not requiring a biological DMARD.
|